GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Itoco Inc (OTCPK:ITMC) » Definitions » Interest Expense

Itoco (ITMC) Interest Expense : $-0.27 Mil (TTM As of Sep. 2010)


View and export this data going back to 2009. Start your Free Trial

What is Itoco Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Itoco's interest expense for the three months ended in Sep. 2010 was $ -0.06 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2010 was $-0.27 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Itoco's Operating Income for the three months ended in Sep. 2010 was $ -0.18 Mil. Itoco's Interest Expense for the three months ended in Sep. 2010 was $ -0.06 Mil. Itoco did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Itoco Interest Expense Historical Data

The historical data trend for Itoco's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Itoco Interest Expense Chart

Itoco Annual Data
Trend Dec08 Dec09
Interest Expense
-0.13 -0.61

Itoco Quarterly Data
Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.26 -0.10 - -0.11 -0.06

Itoco Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2010 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Itoco  (OTCPK:ITMC) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Itoco's Interest Expense for the three months ended in Sep. 2010 was $-0.06 Mil. Its Operating Income for the three months ended in Sep. 2010 was $-0.18 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2010 was $1.20 Mil.

Itoco's Interest Coverage for the quarter that ended in Sep. 2010 is calculated as

Itoco did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.


Itoco (ITMC) Business Description

Traded in Other Exchanges
N/A
Address
50 West Liberty Street, Suite 880, Reno, NV, USA, 89501
Itoco Inc is focused on developing and bringing biotech products to the market via co-development and joint venture arrangements with various companies. The company is currently examining various technologies that seek to control and/or identify bio-contaminants such as viruses and bacteria.